Business
MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%
New Data from IQVIA Supports Potential $3 Billion Annual Market BALTIMORE, Nov. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or
About this update from Mira Pharmaceuticals, Inc.
[{"type":"text","content":"New Data from IQVIA Supports Potential $3 Billion Annual Market\nBALTIMORE, Nov. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (\"MIRA\" or the \"Company\"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic diseases and neuropsychiatric disorders, today announced results from recent studies that indicate Ketamir-2's oral bioavailability is predicted to be approximately 80%.\n\nMIRA recently unveiled its revolutionary product, Ketamir-2, which is designed to potentially reshape the landscape of depression treatment.\nKetamir-2 lead developer Adam Kaplin, MD, Ph.D., President and Chief Scientific Officer of MIRA Pharmaceuticals, commented: \"Ketamir-2, an innovative analog of Ketamine developed as an oral formulation, signifies a breakthrough for Major Depressive Disorder and MDSI. Tailored for convenient home use, it offers administration ease and aims for fewer side effects, eliminating the need for clinical supervision associated with existing treatments like Spravato.\"\nRecent laboratory invitro studies of the CaCO-2 model of human intestinal drug absorption suggested Ketamir-2's superior absorption when taken by mouth compared to Ketamine, with key findings indicating a dramatic 41% net absorption (amount of drug absorbed minus the amount pumped back into the gut), signifying significantly improved uptake compared to Ketamine's -15% (where the amount of drug pumped back into the gut from the bloodstream, for eventual excretion, exceeded the amount absorbed into the body).\nGiven oral Ketamine's previously determined 23% bioavailability when taken by mouth, Ketamir-2's adjusted oral bioavailability based on the CaCO-2 results is predicted to be around 80%1. This bioavailability is more than double that of oral or intranasal absorption of ketamine, promising a potential shift to oral, home administration, granting patients greater autonomy, convenience, and accessibility to effective depression treatment.\nAdditionally, a valuation analysis conducted by IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, forecasts that by 2035, Ketamir-2 could generate an average annual sales of $3 billion, with estimates rising to up to $7.8 billion. This projection highlights Ketamir-2's potential to bridg...